FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA

🇮🇹Italy

Country: 🇮🇹Italy

Ownership: Private, Subsidiary

Employees: -

Market Cap: -

Website: http://www.fpoircc.it

Clinical Trials

Comparison of Multi-parametric and Bi-parametric Magnetic Resonance Imaging in Men With Suspicion of Prostate Cancer

Not Applicable

Completed

Conditions: Prostatic Neoplasm

Interventions: Diagnostic Test: bi-parametric MRI
Diagnostic Test: multi-parametric MRI

First Posted Date: 2018-10-03

Last Posted Date: 2020-08-12

Lead Sponsor: Fondazione del Piemonte per l'Oncologia

Target Recruit Count: 391

Registration Number: NCT03693703

Locations: 🇮🇹
Fondazione del Piemonte per l'Oncologia - Candiolo Cancer Institute, Candiolo, Turin, Italy

Study of Trastuzumab-emtansine in Patients With HER2-positive Metastatic Colorectal Cancer Progressing After Trastuzumab and Lapatinib.

Phase 2

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Trastuzumab emtansine

First Posted Date: 2018-02-01

Last Posted Date: 2018-10-31

Lead Sponsor: Fondazione del Piemonte per l'Oncologia

Target Recruit Count: 13

Registration Number: NCT03418558

Locations: 🇮🇹
Fondazione del Piemonte per l'Oncologia, Candiolo, Italy
🇮🇹
Grande Ospedale Metropolitano Niguarda, Milano, Italy
🇮🇹
IOV - Istituto Oncologico Veneto, Padova, Italy

Genotyping of Metastatic Colorectal Cancer Patients for Precision Medicine Clinical Trials

Conditions: Metastatic Colorectal Cancer

First Posted Date: 2017-11-22

Last Posted Date: 2018-10-30

Lead Sponsor: Fondazione del Piemonte per l'Oncologia

Target Recruit Count: 1000

Registration Number: NCT03350412

Locations: 🇮🇹
Policlinico Universitario Campus Biomedico, Roma, Italy
🇮🇹
AOU Policlinico S Orsola - Malpighi, Bologna, Italy
🇮🇹
Fondazione del Piemonte per l'Oncologia, Candiolo, Italy

and more 2 locations

Target Therapies Resistance Molecular Profiling in Patients With Neoplastic Disease

Conditions: Solid Tumors

First Posted Date: 2017-11-20

Last Posted Date: 2017-11-20

Lead Sponsor: Fondazione del Piemonte per l'Oncologia

Target Recruit Count: 2500

Registration Number: NCT03347318

Locations: 🇮🇹
Policlinico S.Orsola Malpighi, Bologna, Italy
🇮🇹
Istituto Di Candiolo - Fondazione Del Piemonte Per L'Oncologia (FPO-Irccs), Candiolo, Italy
🇮🇹
Ospedale Regionale Umberto Parini, Aosta, Italy

and more 12 locations

Rechallenge With Panitumumab Driven by RAS Dynamic of Resistance

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: Panitumumab 20 MG/ML Intravenous Solution [VECTIBIX]
Diagnostic Test: Molecular Screening

First Posted Date: 2017-07-24

Last Posted Date: 2022-08-25

Lead Sponsor: Fondazione del Piemonte per l'Oncologia

Target Recruit Count: 32

Registration Number: NCT03227926

Locations: 🇮🇹
Istituto Nazionale Tumori - IRCCS, Milano, Via Giacomo Venezian, 1, Italy
🇮🇹
Grande Ospedale Metropolitano Niguarda, Milano, Italy
🇮🇹
Fondazione del Piemonte per l'Oncologia - IRCCS, Candiolo, Italy

and more 1 locations

Evaluation of Trastuzumab in Combination With Lapatinib or Pertuzumab in Combination With Trastuzumab-Emtansine to Treat Patients With HER2-positive Metastatic Colorectal Cancer

Phase 2

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Trastuzumab, Lapatinib
Drug: Pertuzumab, trastuzumab-emtansine

First Posted Date: 2017-07-21

Last Posted Date: 2018-10-30

Lead Sponsor: Fondazione del Piemonte per l'Oncologia

Target Recruit Count: 54

Registration Number: NCT03225937

Locations: 🇮🇹
AOU Città della Salute e della Scienza di Torino, Torino, Italy
🇮🇹
Fondazione del Piemonte per l'Oncologia - IRCCS, Candiolo, Please Select, Italy
🇮🇹
Grande Ospedale Metropolitano Niguarda, Milano, Italy

and more 4 locations

Radiotherapy After Mastectomy for Breast Cancer Patients at Increased Risk of Local Recurrence

Not Applicable

Conditions: Breast Cancer

Interventions: Radiation: Partial chest wall radiation therapy

First Posted Date: 2017-04-05

Last Posted Date: 2017-09-05

Lead Sponsor: Fondazione del Piemonte per l'Oncologia

Target Recruit Count: 28

Registration Number: NCT03101683

Prospective Observational Study of Antitumor Activity Correlation Between Hormonal Therapy and Expression miRNA100

Conditions: Breast Cancer

First Posted Date: 2016-11-01

Last Posted Date: 2016-11-03

Lead Sponsor: Fondazione del Piemonte per l'Oncologia

Target Recruit Count: 180

Registration Number: NCT02950207

Locations: 🇮🇹
Fondazione del Piemonte per l'Oncologia-IRCCS Candiolo, Candiolo, Turin, Italy

MR-targeted vs. Random TRUS-guided Prostate Biopsy

Not Applicable

Conditions: Prostate Cancer

Interventions: Device: TRUS-guided prostate biopsy
Device: MR-guided in-bore prostate biopsy

First Posted Date: 2016-02-09

Last Posted Date: 2016-08-22

Lead Sponsor: Fondazione del Piemonte per l'Oncologia

Target Recruit Count: 90

Registration Number: NCT02678481

Locations: 🇮🇹
Fondazione del Piemonte per l'Oncologia - Candiolo Cancer Institute, Candiolo, Turin, Italy

Biliary Cancer in Italy: a Study on Cholangiocarcinoma cAUSEs and Risk Factors

Conditions: Cholangiocarcinoma

First Posted Date: 2016-01-27

Last Posted Date: 2016-09-23

Lead Sponsor: Fondazione del Piemonte per l'Oncologia

Target Recruit Count: 500

Registration Number: NCT02665494

Locations: 🇮🇹
Azienda Ospedaliera S.Croce e Carle Cuneo, Cuneo, Italy
🇮🇹
Fondazione del Piemonte per l' Oncologia - IRCCS Candiolo, Candiolo, Torino, Italy
🇮🇹
Istituto Tumori Giovanni Paolo II Bari - IRCCS, Bari, Italy

and more 9 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy